Peter Koelblinger - Concepedia

Author

Peter Koelblinger

Paracelsus Medical University ORCID

Also Known As

Koelblinger, Peter, P. Koelblinger, Peter Koelblinger

Publications

791

Citations

H-Index

Concepts

All Affiliations

Paracelsus Medical University University Hospital of Zurich Unfallkrankenhaus Salzburg Medical University of Graz University of Zurich

About

Peter Koelblinger is an author at Paracelsus Medical University specializing in pathology, covid-19, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	20
2	Public Health	1	1	20
3	Epidemiology	1	1	20
4	Global Health	1	1	20
5	Pathology	1	1	20

Peter Koelblinger

Publications

350

Citations

H-Index

Page 1

	Year	Citations
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany Julia Maria Ressler, Matthias Karasek, Lukas Koch, Journal for ImmunoTherapy of Cancer	2021	50
Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients Maria‐Filothei Lazaridou, Evamaria Gonschorek, Chiara Massa, OncoImmunology	2020	39
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies Inês Pires da Silva, Isabella C. Glitza, Lauren E. Haydu, Pigment Cell & Melanoma Research	2019	34
Increased tumour cell <scp>PD</scp>‐L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas Peter Koelblinger, Michael Emberger, Matthias Drach, Journal of the European Academy of Dermatology and Venereology	2018	26
Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma Maria‐Filothei Lazaridou, Chiara Massa, Diana Handke, Journal of Clinical Medicine	2020	26
Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity Daniela D. Weber, Sepideh Aminzadeh-Gohari, Maheshwor Thapa, Cancer & Metabolism	2022	26
Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (<scp>NIVOSQUACS</scp> study)—Phase <scp>II</scp> data covering impact of concomitant haematological malignancies Roland Lang, Tobias Welponer, Erika Richtig, Journal of the European Academy of Dermatology and Venereology	2023	22
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma Natalie P Graf, Peter Koelblinger, N. Galliker, Journal of the European Academy of Dermatology and Venereology	2018	21
The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma Corina Kaufmann, Werner Kempf, Joanna Mangana, Histopathology	2020	20
Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts Daniela D. Weber, Maheshwor Thapa, Sepideh Aminzadeh-Gohari, Cancers	2021	20

Page 1